Ildiko E. Phillips
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ildiko E. Phillips has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Bidish Patel
Mass General Cancer Center, Harvard Medical School, Charlestown, Massachusetts
15 shared publications - David T. Ting
Krantz Family Center for Cancer Research, Mass General Brigham Cancer Institute, Harvard Medical School, Boston, Massachusetts
15 shared publications - Joshua R. Kocher
Mass General Cancer Center, Harvard Medical School, Charlestown, Massachusetts
15 shared publications - Katherine H. Xu
Mass General Cancer Center, Harvard Medical School, Charlestown, Massachusetts
15 shared publications - Linda T. Nieman
Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
15 shared publications - Michael J. Raabe
Mass General Cancer Center, Harvard Medical School, Charlestown, Massachusetts
15 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S3. Key resources table
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S3. Key resources table
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S7 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Figure S1. LINE-1 ORF1p function in PDAC and other cell lines. Supplementary Figure S2. Titration of Dox concentration to rescue ORF1p expression and evaluation of micronuclei-mediated STING activation. Supplementary Figure S3. ORF1p knockdown sensitizes repeat RNA-induced IFN response. Supplementary Figure S4. ORF1p cellular localization and evaluation of RNA editing protein function. Supplementary Figure S5. EM-related gene expression and response to drugs upon ORF1 knockdown. Supplementary Figure S6. ORF1 knockdown in vivo suppresses tumor progression by altering the TME. Supplementary Figure S7. Analysis of single-cell spatial neighborhoods.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S7 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Figure S1. LINE-1 ORF1p function in PDAC and other cell lines. Supplementary Figure S2. Titration of Dox concentration to rescue ORF1p expression and evaluation of micronuclei-mediated STING activation. Supplementary Figure S3. ORF1p knockdown sensitizes repeat RNA-induced IFN response. Supplementary Figure S4. ORF1p cellular localization and evaluation of RNA editing protein function. Supplementary Figure S5. EM-related gene expression and response to drugs upon ORF1 knockdown. Supplementary Figure S6. ORF1 knockdown in vivo suppresses tumor progression by altering the TME. Supplementary Figure S7. Analysis of single-cell spatial neighborhoods.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S2. Classification of FOVs based on LINE-1 ORF1p expression.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S2. Classification of FOVs based on LINE-1 ORF1p expression.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S1. List of proteins localized in PBs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S1. List of proteins localized in PBs.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
DEG table1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
List of differential expressed genes
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessDEG table1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
List of differential expressed genes
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data2 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
List of concordant differential expressed genes between cell lines and patient tumors
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data2 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
List of concordant differential expressed genes between cell lines and patient tumors
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 - Representation1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Table outlines patient representation in general and on study
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 - Representation1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Table outlines patient representation in general and on study
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Elraglusib dosing of PDAC lines. Principle component analysis of spatial gene expression focused on Epithelial and Immune compartments. Stromal compartment spatial gene analysis. UMAPs of snRNA seq analysis.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Elraglusib dosing of PDAC lines. Principle component analysis of spatial gene expression focused on Epithelial and Immune compartments. Stromal compartment spatial gene analysis. UMAPs of snRNA seq analysis.
- 9 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (5) , 869-882
Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Purpose: Pancreatic ductal adenocarcinoma (PDAC) cells exist on a spectrum of epithelial (E) and quasi-mesenchymal (QM) transcriptional states, with differences in sensitivity to FOLFIRINOX (FFX). Glycogen synthase kinase 3β (GSK-3β) is a key regulator of PDAC cell epithelial-to-mesenchymal transition (EMT). Patients and Methods: In vitro analysis of PDAC cell lines combined with multiomic analysis of data from a GSK-3β inhibitor trial (NCT05077800) was conducted to evaluate treatment effects on EMT. Results: GSK-3β inhibition with elraglusib (ELRA) drives QM PDAC cells toward an E state, demarcated by decreased transcription of QM genes FN1 and TGFB1 and an induction of E genes KRT8 and CEACAM6. A comparison of differentially expressed genes (DEG) in PDAC cell lines with tumors from patients with PDAC treated in a safety cohort combining FFX, ELRA, and losartan demonstrated 97 overlapping DEGs with concordant directional changes. ELRA treatment consistently suppressed EMT pathway expression. The synergy of ELRA with cytotoxic doses of FFX in 3D culture was observed only in QM PDAC lines. The FFX/ELRA combination demonstrated initial evidence of clinical benefit, with three of six patients experiencing a partial response (PR) for a duration of at least 20 months. Interestingly, PRs were observed in patients with tumors demonstrating a baseline high proportion of QM cells that transitioned to E predominant tumors with ELRA treatment. Lastly, the influx of M1 tumor-associated macrophages, CD4/CD8 lymphocytes, and NK cells was observed with ELRA clinical response using a combination of GeoMx, snRNA-seq, and ferumoxytol-enhanced MRI. Conclusions: GSK-3β blockade synergizes with FFX by modulating PDAC plasticity while promoting the development of a tumor-suppressive immune microenvironment.
- 9 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (5) , 869-882
Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Purpose: Pancreatic ductal adenocarcinoma (PDAC) cells exist on a spectrum of epithelial (E) and quasi-mesenchymal (QM) transcriptional states, with differences in sensitivity to FOLFIRINOX (FFX). Glycogen synthase kinase 3β (GSK-3β) is a key regulator of PDAC cell epithelial-to-mesenchymal transition (EMT). Patients and Methods: In vitro analysis of PDAC cell lines combined with multiomic analysis of data from a GSK-3β inhibitor trial (NCT05077800) was conducted to evaluate treatment effects on EMT. Results: GSK-3β inhibition with elraglusib (ELRA) drives QM PDAC cells toward an E state, demarcated by decreased transcription of QM genes FN1 and TGFB1 and an induction of E genes KRT8 and CEACAM6. A comparison of differentially expressed genes (DEG) in PDAC cell lines with tumors from patients with PDAC treated in a safety cohort combining FFX, ELRA, and losartan demonstrated 97 overlapping DEGs with concordant directional changes. ELRA treatment consistently suppressed EMT pathway expression. The synergy of ELRA with cytotoxic doses of FFX in 3D culture was observed only in QM PDAC lines. The FFX/ELRA combination demonstrated initial evidence of clinical benefit, with three of six patients experiencing a partial response (PR) for a duration of at least 20 months. Interestingly, PRs were observed in patients with tumors demonstrating a baseline high proportion of QM cells that transitioned to E predominant tumors with ELRA treatment. Lastly, the influx of M1 tumor-associated macrophages, CD4/CD8 lymphocytes, and NK cells was observed with ELRA clinical response using a combination of GeoMx, snRNA-seq, and ferumoxytol-enhanced MRI. Conclusions: GSK-3β blockade synergizes with FFX by modulating PDAC plasticity while promoting the development of a tumor-suppressive immune microenvironment.
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Data from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Repeat element viral mimicry is a common feature in pancreatic ductal adenocarcinoma (PDAC) that requires mechanisms to manage this repeat “viral” load and attenuate innate immune responses. In this study, we show that the long interspersed nuclear element 1 (LINE-1) open reading frame 1 protein (ORF1p) in PDAC cells plays a role in shielding repeat RNAs from activating a pathogen recognition receptor–mediated antiviral response that is independent of retrotransposition. Suppression of ORF1p using short hairpin RNA induces innate immune responses through the double-stranded RNA (dsRNA) sensors RIG-I and MAVS. Low ORF1p PDAC cell lines have suppressed expression of pathogen recognition receptors demonstrating convergent mechanisms to suppress innate immune signaling. Localization of ORF1p in processing bodies with the dsRNA helicase MOV10 was found to be important for these antiviral responses. Loss of ORF1p resulted in significant growth reduction in tumorspheres and mouse xenografts with an enriched epithelial cell state, and high ORF1p expression was associated with worsened survival in a cohort of human patients with PDAC.Significance:This study uncovers PDAC-specific mechanisms that dampen immune responses to viral-repeat RNA via long interspersed nuclear element 1 ORF1p. Suppression of ORF1p activates antiviral responses, reducing tumor growth and epithelial–mesenchymal transition. High ORF1p expression correlates with poor prognosis, highlighting its potential as a therapeutic target for PDAC.
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Repeat element viral mimicry is a common feature in pancreatic ductal adenocarcinoma (PDAC) that requires mechanisms to manage this repeat “viral” load and attenuate innate immune responses. In this study, we show that the long interspersed nuclear element 1 (LINE-1) open reading frame 1 protein (ORF1p) in PDAC cells plays a role in shielding repeat RNAs from activating a pathogen recognition receptor–mediated antiviral response that is independent of retrotransposition. Suppression of ORF1p using short hairpin RNA induces innate immune responses through the double-stranded RNA (dsRNA) sensors RIG-I and MAVS. Low ORF1p PDAC cell lines have suppressed expression of pathogen recognition receptors demonstrating convergent mechanisms to suppress innate immune signaling. Localization of ORF1p in processing bodies with the dsRNA helicase MOV10 was found to be important for these antiviral responses. Loss of ORF1p resulted in significant growth reduction in tumorspheres and mouse xenografts with an enriched epithelial cell state, and high ORF1p expression was associated with worsened survival in a cohort of human patients with PDAC.Significance:This study uncovers PDAC-specific mechanisms that dampen immune responses to viral-repeat RNA via long interspersed nuclear element 1 ORF1p. Suppression of ORF1p activates antiviral responses, reducing tumor growth and epithelial–mesenchymal transition. High ORF1p expression correlates with poor prognosis, highlighting its potential as a therapeutic target for PDAC.